Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.
Saved in:
| Title: | Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma. |
|---|---|
| Authors: | Karam JA; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jakaram@mdanderson.org.; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. jakaram@mdanderson.org., Msaouel P; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. PMsaouel@mdanderson.org.; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. PMsaouel@mdanderson.org.; David H. Koch Center for Applied Research of Genitourinary Cancers, The University of Texas, MD Anderson Cancer Center, Houston, TX, 77030, USA. PMsaouel@mdanderson.org., Haymaker CL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Matin SF; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Campbell MT; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Zurita AJ; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shah AY; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Marmonti E; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Duose DY; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Parra ER; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Soto LMS; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Laberiano-Fernandez C; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Lozano M; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Abraham A; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Hallin M; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA., Chin CD; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA., Olson P, Der-Torossian H; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA., Yan X; Mirati Therapeutics, Inc., San Diego, CA, 92121, USA., Tannir NM; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wood CG; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. |
| Source: | Nature communications [Nat Commun] 2023 May 10; Vol. 14 (1), pp. 2684. Date of Electronic Publication: 2023 May 10. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-023-38342-7 |
